PDgrastim (filgrastim biosimilar)
/ Pooyesh Darou
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
October 24, 2025
Effect of culture media and fermentation process on the refolding and purification of rh-GCSF.
(PubMed, Protein Expr Purif)
- "The purified samples were compared to Neupogen® and PDgrastim reference standards using Western blotting, size exclusion chromatography, and reverse-phase high-performance liquid chromatography. The analysis confirmed that all proteins were correctly refolded and exhibited a purity exceeding 90 % after purification. The highest protein recovery percentage and purity of rh-GCSF with the lowest endotoxin content was achieved using M9 media in fed-batch culture."
Journal • Hematological Disorders • Neutropenia
April 26, 2021
Comparing the efficacy and side-effects of PDLASTA® (Pegfilgrastim) with PDGRASTIM® (Filgrastim) in breast cancer patients: a non-inferiority randomized clinical trial.
(PubMed, BMC Cancer)
- "It seems that PDL is non-inferior in efficacy and also less toxic than PDG. Since PDL can be administered in a single dose and is also less costly, it can be regarded as a cost-effective drug for the treatment of chemotherapy-induced neutropenia."
Adverse events • Clinical • Head-to-Head • Journal • Breast Cancer • Hematological Disorders • Musculoskeletal Pain • Neutropenia • Oncology • Pain • Solid Tumor
October 05, 2018
Quality Comparison of Biosimilar and Copy Filgrastim Products with the Innovator Product.
(PubMed, Pharm Res)
- "Except for the deviating specific activities of the two copy filgrastim products, we found no substantial differences in product quality between the filgrastim products studied."
Journal
1 to 3
Of
3
Go to page
1